ClinicalTrials.gg
Active, not recruitingNCT07000136AZURE-HeFHUpdated Nov 9, 2026

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

A Phase 3 interventional study of AZD0780 and Placebo in Heterozygous Familial Hypercholesterolaemia, sponsored by AstraZeneca. Active, not recruiting at 133 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
473
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study.

The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.

Read the detailed description

This is a randomised, double-blind, placebo-controlled, parallel-group Phase III study to evaluate the effect on the reduction of LDL-C and the safety and tolerability of AZD0780 versus placebo, administered as xx mg once daily orally, on top of a high intensity lipid-lowering regimen. The target population is adults ≥ 18 years of age with HeFH either with ASCVD and LDL-C ≥ 55 mg/dL, or without clinical ASCVD and LDL-C ≥ 70 mg/dL. The study will be conducted at approximately 170 centres in approximately 25 countries.

The screening period is up to 14 days (and may be conditionally extended), starts at the date of signed informed consent, and ends on the day before the randomisation visit. Participants will be randomised in a 2:1 ratio to either AZD0780 or placebo for a treatment period of 52 weeks and a 10-day safety follow-up. Those randomised to the AZD0780 group will receive AZD0780 xx mg orally once daily during the treatment period, while those in the placebo group will receive matching placebo. The study will include approximately 405 randomised participants. An independent data monitoring committee will, on a regular basis, review accumulating data from the study, evaluate adverse effects of the IMP, and make recommendations regarding whether to halt or modify the study.

02

Conditions studied

  • Heterozygous Familial Hypercholesterolaemia

Keywords

  • Low-Density Lipoprotein Cholesterol
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

•≥ 18 years of age at the time of signing the ICF.

  • Diagnosis of HeFH by genetic confirmation or a definite clinical diagnosis, ie, a score > x using the Dutch Lipid Network [Nordestgaard et al 2013] or equivalent as per internationally accepted diagnostic algorithms (AHA [Gidding et al 2015], US MEDPED [Williams et al 1993], Simon Broome [Scientific Steering Committee on behalf of the Simon Broome Register Group 1991], or Japanese Atherosclerosis Society Guidelines [Okamura et al 2024])
  • Fasting serum by central laboratory at screening as follows: LDL-C ≥ 55 mg/dL (≥ 1.4 mmol/L) in participants with HeFH and clinical ASCVD or ≥ 70 mg/dL (≥ 1.8 mmol/L) in HeFH without clinical ASCVD. Clinical ASCVD is defined as MI, stable or unstable angina, coronary or other arterial revascularisation, ischaemic stroke, or peripheral artery disease.
  • Participants should receive a background lipid lowering regimen anticipated to achieve at least a \~50% reduction in LDL-C. Except in cases of intolerance, the regimen should include a high intensity statin therapy or lower intensity statin therapy in combination with an oral agent with proven outcome benefit (eg, ezetimibe and/or bempedoic acid).

Thus, the background lipid-lowering therapy must consist of one of the following:

- A high intensity LDL lowering regimen (i) A high intensity statin regimen, as defined by country specific guidelines - Oral combination therapy with ezetimibe and/or bempedoic acid is strongly recommended OR: (ii) A lower intensity statin regimen in combination with ezetimibe and/or bempedoic acid :

OR:

- A maximally tolerated statin regimen - Oral combination therapy with ezetimibe and/or bempedoic acid is strongly recommended.

Participants must achieve a stable background lipid lowering therapy > 28 days before screening.

Exclusion criteria

Exclusion criteria:

  • Homozygous familial hypercholesterolaemia, LDL apheresis or plasma apheresis within 12 months prior to screening, or any other underlying known disease or condition that may interfere with interpretation of the clinical study results as judged by the Investigator.
  • Any of the following laboratory values at screening:

    • Calculated \< 15 mL/min/1.73 m2
    • or ALT > 3 ×
    • TBL > 2 × ULN (except for patients with Gilberts syndrome, where TBL 3 × ULN is acceptable provided direct \< 1.5 × ULN)
    • Fasting triglycerides ≥ 400 mg/dL (≥ 4.52 mmol/L)
    • Creatine kinase > 5 × ULN
    • Urine albumin-to-creatinine ratio ≥ 500 mg/g
  • Uncontrolled type 2 diabetes mellitus defined as ≥ 9.5% at screening
  • Inadequately treated hypothyroidism defined as TSH > 1.5 ULN at screening or participants whose thyroid replacement therapy was initiated or modified within the last 3 months prior to screening
  • Use of mipomersen or lomitapide (cholesterol-lowering medications) within 12 months prior to screening or planned use during the study.
  • Use of gemfibrozil within 1 week prior to screening or planned use during the study.
  • Use of PCSK-9 inhibitors: evolocumab/alirocumab within 12 weeks of the screening visit or planned use during the study or inclisiran within 18 months of the screening visit or planned use during the study. Any other approved PCSK-9 inhibitor use within 5 half lives prior to the screening visit or planned use during the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
473 participants (actual)

Study arms

  • Experimental
    AZD0780

    Participants will receive daily oral dose of AZD0780

    Drug: AZD0780

  • Placebo comparator
    Placebo

    Participants will receive daily oral dose of placebo

    Drug: Placebo

Interventions

  • Participants will receive daily oral dose of AZD0780

  • DrugPlacebo

    Participants will receive daily oral dose of placebo

06

What researchers measure

Primary outcomes

  1. Relative change in LDL-C from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks

    Time frame: Baseline - 12 weeks

Secondary outcomes

  1. Relative change in LDL-C from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks in patients on background statin therapy at baseline

    Time frame: Baseline - 12 weeks

  2. Indicator for LDL-C < 70 mg/dL (< 1.8 mmol/L) at 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on the probability of LDL-C \< 70 mg/dL at 12 weeks in patients with baseline LDL-C ≥ 70 mg/dL

    Time frame: Baseline - 12 weeks

  3. Indicator for LDL-C < 55 mg/dL (< 1.4 mmol/L) at 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on the probability of LDL-C \< 55 mg/dL at 12 weeks

    Time frame: Baseline - 12 weeks

  4. Relative change in LDL-C from baseline to 28 weeks

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 28 weeks

    Time frame: Baseline - 28 weeks

  5. Relative change in LDL-C from baseline to 52 weeks

    To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 52 weeks

    Time frame: Baseline - 52 weeks

  6. Relative change in Apo B from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on apolipoprotein (Apo) B at 12 weeks

    Time frame: Baseline - 12 weeks

  7. Relative change in non-HDL-C from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on non-high-density lipoprotein cholesterol (HDL-C) at 12 weeks

    Time frame: Baseline - 12 weeks

  8. Relative change in total cholesterol from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on total cholesterol at 12 weeks

    Time frame: Baseline - 12 weeks

  9. Relative change in Lp(a) from baseline to 12 weeks

    To compare the effect of treatment with AZD0780 versus placebo on lipoprotein(a) (Lp\[a\]) at 12 weeks

    Time frame: Baseline - 12 weeks

07

Study locations

133 sites
  • Research Site
    Garden Grove, California 92844, United States
  • Research Site
    San Diego, California 92111, United States
  • Research Site
    Miami Lakes, Florida 33016, United States
  • Research Site
    Orlando, Florida 32807, United States
  • Research Site
    Peachtree Corners, Georgia 30092, United States
  • Research Site
    Chicago, Illinois 60607, United States
  • Research Site
    Hammond, Louisiana 70403, United States
  • Research Site
    Las Vegas, Nevada 89119, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Morganton, North Carolina 28655, United States
  • Research Site
    Cincinnati, Ohio 45227, United States
  • Research Site
    Lima, Ohio 45801, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Houston, Texas 77043, United States
  • Research Site
    Humble, Texas 77338, United States
  • Research Site
    Kingwood, Texas 77345, United States
  • Research Site
    McAllen, Texas 78503, United States
  • Research Site
    Mesquite, Texas 75149, United States
  • Research Site
    Redmond, Washington 98052, United States
  • Research Site
    CABA, C1006ACC, Argentina
  • Research Site
    Ciudad Autonoma de Bs As, C1023AAB, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1094AAD, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1425AGC, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Rosario, S2000PBJ, Argentina
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    Campinas, 13060-080, Brazil
  • Research Site
    São Caetano do Sul, 09521-160, Brazil
  • Research Site
    São Paulo, 04004-030, Brazil
  • Research Site
    São Paulo, 04012-180, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Sofia, 1618, Bulgaria
  • Research Site
    Vancouver, British Columbia V6Z2H2, Canada
  • Research Site
    London, Ontario N6A 5A5, Canada
  • Research Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site
    Montreal, Quebec H2W 1R7, Canada
  • Research Site
    Québec, Quebec G1V 4W2, Canada
  • Research Site
    Trois-Rivières, Quebec G9A 4P3, Canada
  • Research Site
    Santiago, 7770086, Chile
  • Research Site
    Valdivia, 5090000, Chile
  • Research Site
    Hradec Králové, 500 05, Czechia
  • Research Site
    Prague, 140 00, Czechia
  • Research Site
    Prague, 19800, Czechia
  • Research Site
    Uherské Hradiště, 686 01, Czechia
  • Research Site
    Aarhus N, 8200, Denmark
  • Research Site
    Copenhagen, 2400, Denmark
  • Research Site
    Esbjerg, 6700, Denmark
  • Research Site
    Herlev, 2730, Denmark
  • Research Site
    Herning, 7400, Denmark
  • Research Site
    Hvidovre, DK-2650, Denmark
  • Research Site
    Viborg, 8800, Denmark
  • Research Site
    Helsinki, 00290, Finland
  • Research Site
    Kuopio, 70210, Finland
  • Research Site
    Tampere, 33520, Finland
  • Research Site
    Turku, 20520, Finland
  • Research Site
    Bron, 69677, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Marseille, 13005, France
  • Research Site
    Paris, 75013, France
  • Research Site
    Saint-Herblain, 44093, France
  • Research Site
    Berlin, 10559, Germany
  • Research Site
    Dresden, 1307, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Budapest, 1036, Hungary
  • Research Site
    Budapest, 1132, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Székesfehérvár, 8000, Hungary
  • Research Site
    Chūōku, 103-0027, Japan
  • Research Site
    Fukushima, 960-1295, Japan
  • Research Site
    Hamamatsu, 432-8580, Japan
  • Research Site
    Ichikawa-shi, 272-8516, Japan
  • Research Site
    Kanazawa, 920-8530, Japan
  • Research Site
    Kanazawa, 920-8641, Japan
  • Research Site
    Kishiwada-shi, 596-8522, Japan
  • Research Site
    Kita-gun, 761-0793, Japan
  • Research Site
    Komatsu-shi, 923-8560, Japan
  • Research Site
    Minatoku, 108-0073, Japan
  • Research Site
    Okayama, 700-0804, Japan
  • Research Site
    Okayama, 702-8055, Japan
  • Research Site
    Osaka, 543-8922, Japan
  • Research Site
    Suita-shi, 564-8565, Japan
  • Research Site
    Takatsuki-shi, 569-8686, Japan
  • Research Site
    Tamanashi, 865-0016, Japan
  • Research Site
    Urasoe-Shi, 901-2102, Japan
  • Research Site
    Yokohama, 247-8581, Japan
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Roosendaal, 4708 AE, Netherlands
  • Research Site
    Rotterdam, 3015 GD, Netherlands
  • Research Site
    Utrecht, 3584 CX, Netherlands
  • Research Site
    Christchurch, 8011, New Zealand
  • Research Site
    Grafton, 1010, New Zealand
  • Research Site
    Bodø, 8005, Norway
  • Research Site
    Grålum, 1712, Norway
  • Research Site
    Oslo, 0369, Norway
  • Research Site
    Oslo, 0586, Norway
  • Research Site
    Trondheim, 7030, Norway

Showing the first 100 of 133 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 2, 2025
StartActual
Jun 10, 2025
Primary completionEst.
Jan 4, 2027
CompletionEst.
Jan 4, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07000136
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 2, 2025
Start date
Jun 10, 2025
Primary completion
Jan 4, 2027 (estimated)
Completion
Jan 4, 2027 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Laroprovstat

Start the discussion